Trial Profile
A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Ozuriftamab vedotin (Primary) ; Pegfilgrastim
- Indications Advanced breast cancer; Head and neck cancer; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors BioAtla
- 26 Mar 2024 According to a BioAtla media release, melanoma patients (n=28) dosed at the Q2W regimen; anticipate two plus scans in April, Data readouts anticipated in May
- 08 Mar 2024 This study has been Discontinued in Italy, according to European Clinical Trials Database record.
- 23 Aug 2023 Planned End Date changed from 30 Jun 2023 to 30 Dec 2025.